Lv42
780 积分 2023-08-02 加入
Targeting hepatic macrophages to treat liver diseases
3天前
已完结
Macrophage‐specific FGF12 promotes liver fibrosis progression in mice
8天前
已完结
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?
1个月前
已完结
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial
1个月前
已完结
Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
1个月前
已完结
Venous thromboembolism
1个月前
已完结
Therapeutic Potential of FXI Inhibitors: Hype or Hope?
1个月前
已完结
Hereditary Angioedema
2个月前
已完结
Complement and Cardiovascular Disease - The Missing Link in Haemodialysis Patients?
2个月前
已完结
Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors
3个月前
已完结
皖公网安备34019202002308
